Vulvovaginal atrophy in the CRETA study: the healthcare professionals’ perception

References

• Portman DJ, Gass ML, Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the international society for the study of women’s sexual health and the North American menopause society. Menopause 2014;21:1–6. doi: 10.1097/GME.0000000000000329.
   PubMed Web of Science ®Google Scholar
• Lev-Sagie A. Vulvar and vaginal atrophy: physiology, clinical presentation, and treatment considerations. Clin Obstet Gynecol 2015;58:476–491. doi: 10.1097/GRF.0000000000000126.
   PubMed Web of Science ®Google Scholar
• Kingsberg SA, Krychman M, Graham S, et al. The women’s EMPOWER survey: identifying women’s perceptions on vulvar and vaginal atrophy and its treatment. J Sex Med 2017;14:413–424. doi: 10.1016/j.jsxm.2017.01.010.
   PubMed Web of Science ®Google Scholar
• Mac Bride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo Clin Proc 2010;85:87–94. doi: 10.4065/mcp.2009.0413.
   PubMed Web of Science ®Google Scholar
• Cagnacci A, Carbone MM, Palma F, AGATA study. Prevalence and association between objective signs and subjective symptoms of vaginal atrophy: the AGATA study. Menopause 2016;23:1139–1145. doi: 10.1097/GME.0000000000000675.
   PubMed Web of Science ®Google Scholar
• Palacios S, Cancelo MJ, Castelo Branco C, et al. Vulvar and vaginal atrophy as viewed by the spanish REVIVE participants: symptoms, management and treatment perceptions. Climacteric 2017;20:55–61. doi: 10.1080/13697137.2016.1262840.
   PubMed Web of Science ®Google Scholar
• Faubion SS, Kingsberg SA, Clark AL, et al. The 2020 genitourinary syndrome of menopause position statement of the North American menopause society. Menopause 2020;27:976–992.
   PubMed Web of Science ®Google Scholar
• Palma F, Volpe A, Villa P, et al. Vaginal atrophy of women in postmenopause. Results from a multicentric observational study: the AGATA study. Maturitas 2016;83:40–44. doi: 10.1016/j.maturitas.2015.09.001.
   PubMed Web of Science ®Google Scholar
• Santoro N, Komi J. Prevalence and impact of vaginal symptoms among postmenopausal women. J Sex Med 2009;6:2133–2142. doi: 10.1111/j.1743-6109.2009.01335.x.
   PubMed Web of Science ®Google Scholar
• Panay N, Palacios S, Bruyniks N, et al. Symptom severity and quality of life in the management of vulvovaginal atrophy in postmenopausal women. Maturitas 2019;124:55–61. doi: 10.1016/j.maturitas.2019.03.013.
   PubMed Web of Science ®Google Scholar
• Palacios S, Nappi RE, Bruyniks N, et al. The European vulvovaginal epidemiological survey (EVES): prevalence, symptoms and impact of vulvovaginal atrophy of menopause. Climacteric 2018;21:286–291. doi: 10.1080/13697137.2018.1446930.
   PubMed Web of Science ®Google Scholar
• DiBonaventura M, Luo X, Moffatt M, et al. The association between vulvovaginal atrophy symptoms and quality of life among postmenopausal women in the United States and Western Europe. J Womens Health (Larchmt) 2015;24:713–722. doi: 10.1089/jwh.2014.5177.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Palacios S, Bruyniks N, et al. The burden of vulvovaginal atrophy on women’s daily living: implications on quality of life from a face-to-face real-life survey. Menopause 2019;26:485–491. doi: 10.1097/GME.0000000000001260.
   PubMed Web of Science ®Google Scholar
• Moral E, Delgado JL, Carmona F, et al. Genitourinary syndrome of menopause. Prevalence and quality of life in spanish postmenopausal women. The GENISSE study. Climacteric 2018;21:167–173. doi: 10.1080/13697137.2017.1421921.
   PubMed Web of Science ®Google Scholar
• Cagnacci A, Xholli A, Venier M. Ospemifene in the management of vulvar and vaginal atrophy: focus on the assessment of patient acceptability and ease of use. Patient Prefer Adherence 2020;14:55–62. doi: 10.2147/PPA.S203614.
   PubMed Web of Science ®Google Scholar
• Faught BM, Soulban G, Yeaw J, et al. Ospemifene versus local estrogen: adherence and costs in postmenopausal dyspareunia. J Comp Eff Res 2019;8:1111–1123. doi: 10.2217/cer-2019-0091.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Palacios S, Panay N, et al. Vulvar and vaginal atrophy in four European countries: evidence from the European REVIVE survey. Climacteric 2016;19:188–197. doi: 10.3109/13697137.2015.1107039.
   PubMed Web of Science ®Google Scholar
• Archer DF, Goldstein SR, Simon JA, et al. Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial. Menopause 2019;26:611–621. doi: 10.1097/GME.0000000000001292.
   PubMed Web of Science ®Google Scholar
• Palacios S, Panay N, Sánchez-Borrego R, et al. Earlier treatment of vulvovaginal atrophy in post-menopausal women may improve treatment outcomes. J Gynecol Women’s Health 2019;16:555928.
   Google Scholar
• Simon JA, Altomare C, Cort S, et al. Overall safety of ospemifene in postmenopausal women from placebo-controlled phase 2 and 3 trials. J Womens Health (Larchmt) 2018;27:14–23. doi: 10.1089/jwh.2017.6385.
   PubMed Web of Science ®Google Scholar
• Sánchez Borrego R, de Diego Pérez de Zabala MV, Alfageme Gullón MJ, et al. Satisfaction and medication adherence in women with vulvovaginal atrophy: the CRETA study. Climateric 2023;26:437–444.
   PubMed Web of Science ®Google Scholar
• Palacios S, Sánchez Borrego R, Suárez Álvarez B, et al. Impact of vulvovaginal atrophy therapies on postmenopausal women’s quality of life. Maturitas 2023;172:46–51. doi: 10.1016/j.maturitas.2023.03.007.
   PubMed Web of Science ®Google Scholar
• Ashkenazy R, Peterson ME. PAUSE: a patient-centric tool to support patient-provider engagement on menopause. Clin Med Insights Womens Health 2018;11:1179562X18757467. doi: 10.1177/1179562X18757467.
   PubMed Web of Science ®Google Scholar
• Faubion SS, Sood R, Kapoor E. Genitourinary syndrome of menopause: management strategies for the clinician. Mayo Clin Proc 2017;92:1842–1849. doi: 10.1016/j.mayocp.2017.08.019.
   PubMed Web of Science ®Google Scholar
• Alvisi S, Baldassarre M, Gava G, et al. Knowledge of genito-urinary syndrome of menopause among Italian gynecologists: the DIADEM survey. Maturitas 2021;143:89–95. doi: 10.1016/j.maturitas.2020.09.011.
   PubMed Web of Science ®Google Scholar
• González Rodríguez SP, Cornellana Puigarnau MJ, Cancelo Hidalgo MJ. Perception and attitudes of Spanish gynecologists against the genitourinary syndrome during the menopause. VUVAGINE Study. Prog Obstet Ginecol 2016;59:134–140.
   Google Scholar
• Baquedano Mainar L, Sánchez Méndez S, Dieste Pérez P, et al. Women’s knowledge about the genitourinary syndrome of menopause: adherence to its treatments in the COVID-19 era in a sample of them: COMEM-GSM study. BMC Womens Health 2021;21:398.
   PubMed Web of Science ®Google Scholar
• Krychman M, Graham S, Bernick B, et al. The women’s EMPOWER survey: women’s knowledge and awareness of treatment options for vulvar and vaginal atrophy remains inadequate. J Sex Med 2017;14:425–433. doi: 10.1016/j.jsxm.2017.01.011.
   PubMed Web of Science ®Google Scholar
• Cumming GP, Herald J, Moncur R, et al. Women’s attitudes to hormone replacement therapy, alternative therapy and sexual health: a web-based survey. Menopause Int 2007;13:79–83. doi: 10.1258/175404507780796424.
   PubMedGoogle Scholar
• Cancelo Hidalgo MJ, Palacios S, del Pino P. Differences in perception of genitourinary syndrome of menopause by gynecologists and postmenopausal women in Spain. Prog Obstet Ginecol 2019;62:436–442.
   Google Scholar
• Cuerva MJ, Gonzalez D, Canals M, et al. The sexual health approach in postmenopause: the five-minutes study. Maturitas 2018;108:31–36. doi: 10.1016/j.maturitas.2017.11.009.
   PubMed Web of Science ®Google Scholar
• Volpicelli Leonard K, Robertson C, Bhowmick A, et al. Perceived treatment satisfaction and effectiveness facilitators among patients with chronic health conditions: a self-reported survey. Interact J Med Res 2020;9:e13029. doi: 10.2196/13029.
   PubMed Web of Science ®Google Scholar
• Bruyniks N, Biglia N, Palacios S, et al. Systematic indirect comparison of ospemifene versus local estrogens for vulvar and vaginal atrophy. Climacteric 2017;20:195–204. doi: 10.1080/13697137.2017.1284780.
   PubMed Web of Science ®Google Scholar
• Reid RL, Black D, Derzko C, et al. Ospemifene: a novel oral therapy for vulvovaginal atrophy of menopause. J Obstet Gynaecol Can 2020;42:301–303. doi: 10.1016/j.jogc.2019.10.039.
   PubMed Web of Science ®Google Scholar
• Goldstein SW, Winter AG, Goldstein I. Improvements to the vulva, vestibule, urethral meatus, and vagina in women treated with ospemifene for moderate to severe dyspareunia: a prospective vulvoscopic pilot study. Sex Med 2018;6:154–161. doi: 10.1016/j.esxm.2018.03.002.
   PubMed Web of Science ®Google Scholar